FDA Approves Daraxonrasib, First Targeted Pancreatic Cancer Pill

A New Weapon Against a Notoriously Deadly Cancer

The Food and Drug Administration has approved daraxonrasib, sold under the brand name Rasonque, marking what many oncologists are calling a landmark moment in the treatment of advanced pancreatic cancer 126. Developed by Revolution Medicines, the once-daily oral pill is the first targeted therapy of its kind for a disease long considered one of the hardest cancers to treat effectively 14.

Pancreatic cancer has historically carried grim survival statistics, with most patients relying on chemotherapy regimens that offer limited benefit. The approval of daraxonrasib represents a shift toward precision medicine for a cancer type that has resisted such approaches for decades 10.

What the Trial Data Showed

The approval was driven by clinical trial results that multiple outlets described as "stunning" and worthy of a genuine breakthrough designation 3. According to reporting from CBS News, patients taking daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy — effectively doubling survival time 7. That figure was echoed across several outlets, which similarly emphasized that patients on the drug nearly doubled their survival compared with a company-run study control group 689.

The drug's mechanism is notable because it targets a genetic mutation in the RAS gene family long labeled "undruggable" by cancer researchers. Coverage framed the approval as finally cracking that biological barrier, a milestone with implications beyond pancreatic cancer given that RAS mutations are implicated in a range of other tumors 4.

Timing and Regulatory Context

Reports differ slightly on the precise approval date, with one account citing August 26, 2026, as the formal FDA sign-off date 4, while another described the decision as occurring on a Wednesday without specifying the exact date 10. Regardless of the precise timeline, the consensus across coverage is that this is a first-of-its-kind approval for a targeted oral therapy in this cancer type 7.

Part of a Broader Wave in Oncology Innovation

The daraxonrasib approval arrives amid a broader stream of advances in cancer treatment research. Separate reporting highlighted an experimental drug helping advanced bladder cancer patients avoid surgery entirely, underscoring a wider trend of therapies aimed at preserving quality of life while extending survival 5. Though unrelated in mechanism, that development reflects the same momentum reshaping expectations for hard-to-treat cancers.

Why It Matters

For patients and families confronting a pancreatic cancer diagnosis — historically associated with survival measured in months rather than years — a therapy that meaningfully extends life expectancy while being administered as a daily pill rather than infused chemotherapy could change treatment expectations significantly. Experts quoted across the coverage describe the approval as a substantial breakthrough, both for its clinical results and for demonstrating that a previously undruggable genetic target can be successfully addressed with modern drug design 34. The approval is likely to intensify research investment into RAS-targeted therapies for other cancers where the same mutations play a role.